Androcles

(redirected from Androclus)
Also found in: Encyclopedia.
Related to Androclus: Androcles

An·dro·cles

 (ăn′drə-klēz′) also An·dro·clus (-kləs)
n.
A legendary Roman slave held to have been spared in the arena by a lion that remembered him as the man who had once removed a thorn from its paw.

Androcles

(ˈændrəˌkliːz) or

Androclus

n
(Classical Myth & Legend) (in Roman legend) a slave whose life was spared in the arena by a lion from whose paw he had once extracted a thorn

An•dro•cles

(ˈæn drəˌkliz)

n.
a Roman slave, in a fable of the 1st–2nd centuries a.d., who was spared in the arena by a lion from whose foot he had once extracted a thorn.
References in periodicals archive ?
Earlier in his career, Bilinsky was CEO of Androclus Therapeutics.
19, discussed below); Androclus and the Lion, from Apion (5.
SAN DIEGO & MILAN, Italy -- Androclus Therapeutics announced the completion of a Phase II clinical trial of AT-001 (dnaJP1), a novel orally administered therapeutic candidate for the treatment of rheumatoid arthritis (RA).
We are encouraged by the results of this Phase II trial, as a validation of Androclus Therapeutics technology platform, epitope-specific immunotherapy.
SAN DIEGO & MILAN, Italy -- Androclus Therapeutics announced publication in Lancet(a) of immunoscreening results of heat-shock protein 60 (hsp60) derived peptides in patients with juvenile idiopathic arthritis (JIA).
SAN DIEGO & MILAN, Italy -- Androclus Therapeutics announced today that it has completed a first institutional financing round to advance its product development programs in rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.
SAN DIEGO & MILAN, Italy -- Androclus Therapeutics has announced that it will be present at Windhover Information's "The Start-Up Forum 2005", taking place May 18-20, 2005 at the Cambridge Marriott in Boston, MA.
SAN DIEGO & MILAN, Italy -- Androclus Therapeutics announced today the formation of a Clinical Advisory Board (CAB) for Neurology, which has been assembled to guide the company in the clinical development of therapeutics for autoimmune diseases such as multiple sclerosis.
SAN DIEGO & MILAN, ITALY -- Androclus Therapeutics, a biotechnology company developing novel products and technologies for treatment of diseases involving the immune system, such as autoimmunity, cancer and infectious diseases, has been granted U.
Androclus Therapeutics announced publication of Phase I/IIa clinical trial results of its AT-001 (dnaJP1) compound for treatment of rheumatoid arthritis (RA) in Proceedings of the National Academy of Sciences*.
Company: Androclus Therapeutics Public Relations Contact: Dr.